Literature DB >> 33826428

Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.

Helen Christou1,2, Zoe Michael1, Fotios Spyropoulos1,2, Yunfei Chen3,2, Dan Rong3,2, Raouf A Khalil3,2.   

Abstract

Pulmonary hypertension (PH) is a serious disease with pulmonary arterial fibrotic remodeling and limited responsiveness to vasodilators. Our data suggest that mild acidosis induced by carbonic anhydrase inhibition could ameliorate PH, but the vascular mechanisms are unclear. We tested the hypothesis that carbonic anhydrase inhibition ameliorates PH by improving pulmonary vascular reactivity and relaxation mechanisms. Male Sprague-Dawley rats were either control normoxic (Nx), or injected with Sugen 5416 (20 mg/kg, sc) and subjected to hypoxia (9% O2) (Su + Hx), or Su + Hx treated with acetazolamide (ACTZ, 100 mg/kg/day, in drinking water). After measuring the hemodynamics, right ventricular hypertrophy was assessed by Fulton's Index; vascular function was measured in pulmonary artery, aorta, and mesenteric arteries; and pulmonary arteriolar remodeling was assessed in lung sections. Right ventricular systolic pressure and Fulton's Index were increased in Su + Hx and reduced in Su + Hx + ACTZ rats. Pulmonary artery contraction to KCl and phenylephrine were reduced in Su + Hx and improved in Su + Hx + ACTZ. Acetylcholine (ACh)-induced relaxation and nitrate/nitrite production were reduced in pulmonary artery of Su + Hx and improved in Su + Hx + ACTZ. ACh relaxation was blocked by nitric oxide (NO) synthase and guanylate cyclase inhibitors, supporting a role of NO-cGMP. Sodium nitroprusside (SNP)-induced relaxation was reduced in pulmonary artery of Su + Hx, and ACTZ enhanced relaxation to SNP. Contraction/relaxation were not different in aorta or mesenteric arteries of all groups. Pulmonary arterioles showed wall thickening in Su + Hx that was ameliorated in Su + Hx + ACTZ. Thus, amelioration of pulmonary hemodynamics during carbonic anhydrase inhibition involves improved pulmonary artery reactivity and NO-mediated relaxation and may enhance responsiveness to vasodilator therapies in PH.

Entities:  

Keywords:  endothelium; hypertension; nitric oxide; smooth muscle; vascular

Mesh:

Substances:

Year:  2021        PMID: 33826428      PMCID: PMC8285620          DOI: 10.1152/ajpregu.00362.2020

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.210


  83 in total

1.  Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance.

Authors:  Javier Sanz; Mbabazi Kariisa; Santo Dellegrottaglie; Susanna Prat-González; Mario J Garcia; Valentin Fuster; Sanjay Rajagopalan
Journal:  JACC Cardiovasc Imaging       Date:  2009-03

2.  The Effect of Acetazolamide and Weight Loss on Intraocular Pressure in Idiopathic Intracranial Hypertension Patients.

Authors:  Rudrani Banik; Mark J Kupersmith; Jui-Kai Wang; Mona K Garvin
Journal:  J Glaucoma       Date:  2019-04       Impact factor: 2.503

3.  SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction.

Authors:  Michiel Alexander de Raaf; Ingrid Schalij; Jose Gomez-Arroyo; Nina Rol; Chris Happé; Frances S de Man; Anton Vonk-Noordegraaf; Nico Westerhof; Norbert F Voelkel; Harm Jan Bogaard
Journal:  Eur Respir J       Date:  2014-05-02       Impact factor: 16.671

Review 4.  Nitric oxide, nitric oxide synthase, and hypertensive vascular disease.

Authors:  R Busse; I Fleming
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 5.  Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators.

Authors:  Charles D Burger
Journal:  COPD       Date:  2009-04       Impact factor: 2.409

6.  Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension.

Authors:  S M Majka; M Skokan; L Wheeler; J Harral; S Gladson; E Burnham; J E Loyd; K R Stenmark; M Varella-Garcia; J West
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-17       Impact factor: 5.464

7.  Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway.

Authors:  Andrea Dallas; Raouf A Khalil
Journal:  Am J Physiol Cell Physiol       Date:  2003-12       Impact factor: 4.249

Review 8.  Pulmonary vascular stiffness: measurement, modeling, and implications in normal and hypertensive pulmonary circulations.

Authors:  Kendall S Hunter; Steven R Lammers; Robin Shandas
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

9.  Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

Authors:  Anne-Marie O'Farrell; Helene A Yuen; Beverly Smolich; Alison L Hannah; Sharianne G Louie; Weiru Hong; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Judith E Karp; Maher Albitar; Julie M Cherrington; Francis J Giles
Journal:  Leuk Res       Date:  2004-07       Impact factor: 3.156

10.  Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.

Authors:  Ralph T Schermuly; Klaus P Kreisselmeier; Hossein A Ghofrani; Hüseyin Yilmaz; Ghazwan Butrous; Leander Ermert; Monika Ermert; Norbert Weissmann; Frank Rose; Andreas Guenther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger
Journal:  Am J Respir Crit Care Med       Date:  2003-09-04       Impact factor: 21.405

View more
  2 in total

Review 1.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

2.  The combined use of acetazolamide and Rhodiola in the prevention and treatment of altitude sickness.

Authors:  Chengzhu Cao; Huan Zhang; Yongchun Huang; Yameng Mao; Lan Ma; Shoude Zhang; Wei Zhang
Journal:  Ann Transl Med       Date:  2022-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.